Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.55 USD

197.55
4,713,450

+1.18 (0.60%)

Updated Aug 23, 2024 04:00 PM ET

Pre-Market: $197.54 -0.01 (-0.01%) 8:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Arpita Dutt headshot

Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues

by Arpita Dutt

Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.

    Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer

    by Zacks Equity Research

    AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.

      Gilead's (GILD) Epclusa Receives Label Expansion in Canada

      by Zacks Equity Research

      Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.

        Arpita Dutt headshot

        Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

        by Arpita Dutt

        Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

          Roche (RHHBY) Announces Positive Data on Leukemia Drug

          by Zacks Equity Research

          Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.

            J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU

            by Zacks Equity Research

            J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.

              Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx

              by Zacks Equity Research

              Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.

                Arpita Dutt headshot

                Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data

                by Arpita Dutt

                Key highlights include Alexion's (ALXN) restructuring plans and promising data from Kura Oncology on its lead pipeline candidate.

                  AbbVie's RA Candidate Meets Primary Endpoint in Phase III

                  by Zacks Equity Research

                  AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.

                    AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb

                    by Zacks Equity Research

                    AbbVie's (ABBV) eczema candidate upadacitinib meets primary endpoints in a phase IIb trial for treating atopic dermatitis. The company aims to advance the candidate to the next study level in 2018.

                      Regeneron's Cemiplimab Gains Breakthrough Therapy Status

                      by Zacks Equity Research

                      Regeneron (REGN) and partner Sanofi's skin cancer candidate cemiplimab gets the FDA-granted Breakthrough Therapy status. The companies also anticipate submitting a BLA in the first-quarter 2018.

                        AbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher

                        by Zacks Equity Research

                        AbbVie (ABBV) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.

                          AbbVie Submits NDA for Endometriosis Candidate to the FDA

                          by Zacks Equity Research

                          AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.

                            Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead

                            by Zacks Equity Research

                            The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.

                              The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                              by Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                Gilead to Fly High with Kite Pharma Acquisition for $11.9B

                                by Zacks Equity Research

                                Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.

                                  The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance

                                  by Zacks Equity Research

                                  The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance

                                    Roche's Gazyva Gets Priority Review for Follicular Lymphoma

                                    by Zacks Equity Research

                                    Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.

                                      Biogen's Humira Biosimilar Imraldi Gets Approval in EU

                                      by Zacks Equity Research

                                      Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.

                                        Roche (RHHBY) Hemophilia A Drug Granted Priority Review

                                        by Zacks Equity Research

                                        Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.

                                          AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada

                                          by Zacks Equity Research

                                          AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.

                                            Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada

                                            by Zacks Equity Research

                                            Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.

                                              Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review

                                              by Zacks Equity Research

                                              Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data

                                                by Arpita Dutt

                                                Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.

                                                  Infinity (INFI) Q2 Loss Wider than Expected, View Intact

                                                  by Zacks Equity Research

                                                  Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.